• Home
  • News
  • Outsourcing Pharma Discusses FDA Guidelines for ADME Programs, Growth Plans with Thierry Van Nieuwenhove Ahead of CPHI Worldwide 2024
Articles & Publications , Thierry Van Nieuwenhove

Outsourcing Pharma Discusses FDA Guidelines for ADME Programs, Growth Plans with Thierry Van Nieuwenhove Ahead of CPHI Worldwide 2024

Thierry Van Nieuwenhove
By: Thierry Van Nieuwenhove
Hexagons on blue gradient background with Quotient Sciences logo

In this article by Outsourcing Pharma,  Quotient Sciences CEO Thierry Van Nieuwenhove shared insights on how the company is adapting to new FDA regulations.

Thierry also discusses how the company is expanding its Translational Pharmaceutics® platforms into new therapeutic areas like mRNA.

Continue reading the full article on Outsourcing Pharma.

Meet the author: Thierry Van Nieuwenhove

Latest news from Quotient Sciences

More News
News & Announcements, Articles & Publications, Artificial Intelligence Andy Lewis on AI‑Enabled Formulation Design and Faster Speed to Clinic By: Andy Lewis
Read More
News & Announcements, Articles & Publications, Early Drug Development, Artificial Intelligence AI's Role in Fast-tracking Early Drug Development; Our ground breaking alliance with Intrepid Labs By: Andy Lewis
Read More
News & Announcements, Articles & Publications, Artificial Intelligence Building Trust in AI‑Enabled Formulation: Insights from Quotient Sciences and Intrepid Labs By: Andy Lewis
Read More
More News
Let's Talk
Your breakthrough therapy deserves momentum, and every day matters. Start a conversation with us today.
Contact Us Therapy Areas